Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

What this study is about

The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

Who can join (things the study team will check)

✅ You may be able to join if…

• Participant must have a primary diagnosis of schizophrenia for at least 1 year established by a comprehensive psychiatric evaluation based on the DSM-5-TR (American Psychiatric Association 2022) criteria and confirmed by MINI for Psychotic Disorder Studies version 7.0.2 at screening.
• Participant must have experienced hospitalization for schizophrenia within 1 year from the screening date.
• Participant must be experiencing residual schizophrenia symptoms and have a PANSS total score ≥70 to ≤ 110 at screening and Day -1.
• Participant much have a PANSS Score of ≥ 4 (moderate or greater) on ≥ 2 of the following Positive Scale (P) items at screening and Day -1:
  • Item 1 (P1; delusions)
  • Item 2 (P2; conceptual disorganization)
  • Item 3 (P3; hallucinatory behavior)
  • Item 6 (P6; suspiciousness/persecution)
• Participant must have a CGI-S score of ≥ 4 at screening and Day -1
• Participant must have a BMI ≥ 18 and ≤ 40 kg/m2.

🚫 You may not be able to join if…

• Participant must not have any primary DSM-5 disorder other than schizophrenia within 12 months before screening
• Participants must not have a newly diagnosed or are experiencing their first treated episode of psychosis or schizophrenia.
• Participant must not have a risk of suicidal behavior as determined by the Investigator's clinical assessment and/or Columbia-suicide Severity Rating Scale (C-SSRS).
• Participant must not have had psychiatric hospitalization(s) for more than 30 days (cumulative) within the 6 months before screening.
• Participant must not have a history of treatment resistance to schizophrenia medications
• Participant must not have decrease in PANSS total score (floor adjusted) between screening and Day -1 of more than 20%.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

• Local Institution - 0133, Bentonville, Arkansas, United States
• Local Institution - 0154, Bentonville, Arkansas, United States
• Local Institution - 0139, Little Rock, Arkansas, United States
• Local Institution - 0021, Little Rock, Arkansas, United States
• Local Institution - 0153, Rogers, Arkansas, United States
• Local Institution - 0190, Anaheim, California, United States
• Local Institution - 0040, Bellflower, California, United States
• Local Institution - 0188, Chino, California, United States
• Local Institution - 0032, Culver City, California, United States
• Local Institution - 0037, Garden Grove, California, United States
• Local Institution - 0068, La Habra, California, United States
• Local Institution - 0128, Lemon Grove, California, United States

+ 49 more sites.

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07686263.